Drugs / Artemisia annua
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04805333 | Mar 2021 → Feb 2025 | ovarian cancer | Frederick R. Ueland, M.D. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03649139 Comparator | Apr 2017 → Oct 2018 | seasonal allergic rhinitis | Beijing Tongren Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-04 | ArtemiLife | Results Plant-based coffee yields promising results in Markey ovarian cancer trial artemilife.com ↗
Preliminary findings of the phase 1 trial show that ArtemiCafe® Decaf is safe and well tolerated by patients at a dose of four cups daily. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-04 | ArtemiLife | Plant-based coffee yields promising results in Markey ovarian cancer trial artemilife.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | artemisia annua | “artemisia annua (sweet sagewort) allergen extract drops” NCT03649139 ↗ |
| Known as | sweet sagewort | “artemisia annua (sweet sagewort) allergen extract drops” NCT03649139 ↗ |
| Route | Other | “administered by means of sublingual drops” NCT03649139 ↗ |